Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
7.30
Dollar change
-0.11
Percentage change
-1.48
%
IndexRUT P/E- EPS (ttm)-0.30 Insider Own3.84% Shs Outstand232.45M Perf Week-6.77%
Market Cap1.70B Forward P/E151.08 EPS next Y0.05 Insider Trans-6.04% Shs Float223.76M Perf Month-22.83%
Income-66.07M PEG- EPS next Q-0.14 Inst Own59.57% Short Float16.23% Perf Quarter11.96%
Sales124.46M P/S13.65 EPS this Y-38.55% Inst Trans51.39% Short Ratio5.77 Perf Half Y76.33%
Book/sh0.72 P/B10.17 EPS next Y111.63% ROA-27.10% Short Interest36.31M Perf Year72.99%
Cash/sh0.79 P/C9.22 EPS next 5Y30.00% ROE-49.83% 52W Range3.16 - 10.13 Perf YTD17.74%
Dividend Est.- P/FCF- EPS past 5Y28.61% ROI-30.26% 52W High-27.94% Beta0.85
Dividend TTM- Quick Ratio4.64 Sales past 5Y146.90% Gross Margin83.23% 52W Low131.01% ATR (14)0.44
Dividend Ex-Date- Current Ratio4.88 EPS Y/Y TTM37.17% Oper. Margin-50.84% RSI (14)32.98 Volatility4.31% 5.52%
Employees267 Debt/Eq0.34 Sales Y/Y TTM138.61% Profit Margin-53.08% Recom1.00 Target Price13.31
Option/ShortYes / Yes LT Debt/Eq0.31 EPS Q/Q-324.64% Payout- Rel Volume1.03 Prev Close7.41
Sales Surprise0.89% EPS Surprise-26.72% Sales Q/Q-22.22% EarningsFeb 22 AMC Avg Volume6.30M Price7.30
SMA20-13.03% SMA50-16.51% SMA20033.40% Trades Volume6,487,801 Change-1.48%
Date Action Analyst Rating Change Price Target Change
Dec-18-23Initiated Raymond James Strong Buy $12
Sep-07-23Initiated H.C. Wainwright Buy $9
Aug-25-23Upgrade Cantor Fitzgerald Neutral → Overweight $5 → $10
Mar-03-23Upgrade Wedbush Neutral → Outperform $3 → $6
Nov-17-22Upgrade Piper Sandler Neutral → Overweight $3 → $8
May-06-22Downgrade Cantor Fitzgerald Overweight → Neutral $7 → $1
Dec-01-21Upgrade Ladenburg Thalmann Neutral → Buy $6
Oct-14-21Downgrade Ladenburg Thalmann Buy → Neutral
Jul-21-21Downgrade Jefferies Buy → Hold $11 → $2
Jul-20-21Downgrade Wedbush Outperform → Neutral $3
Today 04:05PM
Mar-25-24 08:00AM
Mar-16-24 06:00PM
Mar-12-24 04:35PM
Feb-28-24 05:40PM
08:00AM Loading…
Feb-27-24 08:00AM
06:10AM
Feb-23-24 10:16AM
Feb-22-24 06:00PM
05:15PM
04:45PM
04:26PM
04:01PM
Feb-19-24 03:30PM
12:24PM
10:00AM Loading…
Feb-15-24 10:00AM
Feb-09-24 09:55AM
08:50AM
Feb-08-24 12:16PM
12:00PM
09:40AM
Feb-07-24 09:34AM
Feb-06-24 04:00PM
Feb-02-24 02:15AM
Feb-01-24 08:00AM
Jan-29-24 12:35PM
Jan-12-24 07:56AM
Jan-10-24 02:27PM
Jan-08-24 08:00AM
Jan-03-24 08:03AM
11:01PM Loading…
Dec-29-23 11:01PM
Dec-20-23 08:00AM
Dec-14-23 06:40AM
Dec-05-23 09:11AM
Nov-21-23 04:02PM
09:37AM
08:01AM
Nov-17-23 09:00AM
Nov-15-23 04:02PM
Nov-13-23 04:02PM
Nov-10-23 08:05AM
Nov-06-23 08:00AM
Nov-03-23 08:00AM
Nov-02-23 09:40AM
Nov-01-23 10:42AM
Oct-31-23 11:15PM
05:09PM
08:40AM
07:29AM
07:00AM
Oct-30-23 05:42PM
Oct-23-23 08:07AM
Oct-19-23 10:21AM
Oct-18-23 04:31PM
04:02PM
10:42AM
Oct-17-23 07:24PM
07:23PM
07:06PM
07:01PM
Oct-13-23 08:00AM
Oct-11-23 04:17PM
Oct-04-23 08:00AM
Sep-28-23 08:02AM
Sep-25-23 04:15AM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-11-23 08:00AM
Sep-08-23 08:00AM
Sep-07-23 08:00AM
Sep-06-23 12:36PM
12:13PM
Aug-30-23 01:02PM
Aug-28-23 10:22AM
Aug-26-23 03:17PM
Aug-25-23 09:42AM
Aug-24-23 11:05AM
Aug-17-23 09:31AM
Aug-07-23 02:34PM
Aug-04-23 08:29AM
Aug-03-23 08:26AM
Aug-02-23 08:35AM
07:26AM
07:00AM
Jul-27-23 04:05PM
Jul-26-23 07:55AM
Jul-20-23 04:05PM
Jul-16-23 09:37AM
Jul-13-23 08:00AM
Jun-29-23 04:09PM
Jun-19-23 08:00AM
Jun-08-23 09:48AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-23-23 04:05PM
May-22-23 03:30PM
May-17-23 07:30AM
May-15-23 04:05PM
May-09-23 08:00AM
May-06-23 10:08AM
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAMMER ELIZABETH ASee RemarksMar 20 '24Sale7.7386,000664,978312,993Mar 22 04:42 PM
Rosenbaum David P.Chief Development OfficerFeb 26 '24Sale9.205,18347,684175,936Feb 28 06:57 PM
RAAB MICHAELPresident & CEOFeb 20 '24Sale8.7522,917200,4391,319,951Feb 22 04:58 PM
Rodriguez SusanChief Commercial OfficerFeb 20 '24Sale8.756,92860,594452,795Feb 22 04:56 PM
Renz Justin AChief Financial OfficerFeb 20 '24Sale8.755,34146,714304,835Feb 22 05:01 PM
Blanks RobertSee RemarksFeb 20 '24Sale8.755,01743,880368,186Feb 22 04:58 PM
Rosenbaum David P.Chief Development OfficerFeb 20 '24Sale8.755,01743,880378,985Feb 22 06:30 PM
Williams Laura AChief Medical OfficerFeb 20 '24Sale8.754,80342,008380,138Feb 22 04:56 PM
GRAMMER ELIZABETH ASee RemarksFeb 20 '24Sale8.754,43238,764398,993Feb 22 04:57 PM
Felsch Robert OraSee RemarksFeb 20 '24Sale8.752,35220,571184,834Feb 22 04:56 PM
Rosenbaum David P.Chief Development OfficerFeb 20 '24Sale8.752,29420,064181,119Feb 22 06:30 PM
Rosenbaum David P.Chief Development OfficerFeb 08 '24Sale9.1815,344140,846384,002Feb 09 04:14 PM
Rosenbaum David P.Chief Development OfficerJan 08 '24Sale6.6430,000199,200286,596Jan 10 05:36 PM
Renz Justin AChief Financial OfficerDec 26 '23Option Exercise0.9975,00074,250407,426Dec 28 05:44 PM
Renz Justin AChief Financial OfficerDec 26 '23Sale6.36225,0001,430,122182,426Dec 28 05:44 PM
Rosenbaum David P.Chief Development OfficerDec 18 '23Sale6.075,67534,447316,596Dec 20 04:49 PM
Rosenbaum David P.Chief Development OfficerDec 14 '23Sale5.557,00038,850322,271Dec 15 06:13 PM
GRAMMER ELIZABETH ASee RemarksDec 11 '23Sale5.0850,000253,925275,675Dec 13 05:44 PM
Rosenbaum David P.Chief Development OfficerDec 08 '23Sale5.2720,000105,476329,271Dec 08 05:58 PM
Rosenbaum David P.Chief Development OfficerDec 05 '23Sale5.0010,27251,360349,271Dec 06 04:49 PM
Rosenbaum David P.Chief Development OfficerNov 30 '23Sale4.503,00013,500359,543Dec 01 04:47 PM
RAAB MICHAELPresident & CEONov 20 '23Sale4.3611,36849,589867,868Nov 22 05:19 PM
Rodriguez SusanChief Commercial OfficerNov 20 '23Sale4.364,71420,563346,973Nov 22 05:20 PM
Renz Justin AChief Financial OfficerNov 20 '23Sale4.362,87312,533332,426Nov 22 05:20 PM
Rosenbaum David P.Chief Development OfficerNov 20 '23Sale4.362,83512,367362,543Nov 22 05:21 PM
Blanks RobertSee RemarksNov 20 '23Sale4.362,83512,367260,453Nov 22 05:17 PM
Williams Laura AChief Medical OfficerNov 20 '23Sale4.362,58111,259266,191Nov 22 05:22 PM
GRAMMER ELIZABETH ASee RemarksNov 20 '23Sale4.362,38410,399325,675Nov 22 05:19 PM
Felsch Robert OraSee RemarksNov 20 '23Sale4.361,0444,554117,066Nov 22 05:18 PM
Rosenbaum David P.Chief Development OfficerNov 20 '23Sale4.369324,066113,293Nov 22 05:21 PM
Williams Laura AChief Medical OfficerNov 15 '23Sale4.0025,00099,998266,839Nov 17 05:30 PM
Rosenbaum David P.Chief Development OfficerOct 10 '23Sale4.001,6446,576365,378Oct 12 05:09 PM
Rosenbaum David P.Chief Development OfficerSep 08 '23Sale4.552,89713,181367,022Sep 12 05:24 PM
RAAB MICHAELPresident & CEOAug 21 '23Sale3.5511,41940,558876,236Aug 23 04:41 PM
Rodriguez SusanChief Commercial OfficerAug 21 '23Sale3.554,73316,811348,687Aug 23 04:48 PM
Renz Justin AChief Financial OfficerAug 21 '23Sale3.552,88410,243333,849Aug 23 04:42 PM
Blanks RobertSee RemarksAug 21 '23Sale3.552,84610,108263,288Aug 23 04:36 PM
Rosenbaum David P.Chief Development OfficerAug 21 '23Sale3.552,84610,108369,919Aug 23 04:45 PM
Williams Laura AChief Medical OfficerAug 21 '23Sale3.552,5919,203291,839Aug 23 04:46 PM
GRAMMER ELIZABETH ASee RemarksAug 21 '23Sale3.552,3928,496328,059Aug 23 04:39 PM
Felsch Robert OraSee RemarksAug 21 '23Sale3.551,0483,722115,110Aug 23 04:38 PM
Rosenbaum David P.Chief Development OfficerAug 21 '23Sale3.559373,328111,225Aug 23 04:45 PM
Williams Laura AChief Medical OfficerJun 27 '23Sale3.3525,00083,632294,430Jun 29 07:22 PM
Blanks RobertSee RemarksJun 23 '23Option Exercise3.4233,333113,999299,467Jun 27 06:40 PM
Blanks RobertSee RemarksJun 23 '23Sale3.6333,333121,042266,134Jun 27 06:40 PM
RAAB MICHAELPresident & CEOMay 23 '23Sale3.6511,35741,489887,655May 25 08:55 AM
Rodriguez SusanChief Commercial OfficerMay 23 '23Sale3.654,71117,210353,420May 25 08:52 AM
Renz Justin AChief Financial OfficerMay 23 '23Sale3.652,87310,496336,733May 25 08:53 AM
Blanks RobertSee RemarksMay 23 '23Sale3.652,83510,357266,134May 25 08:54 AM
Rosenbaum David P.Chief Development OfficerMay 23 '23Sale3.652,83510,357372,765May 25 08:52 AM
Williams Laura AChief Medical OfficerMay 23 '23Sale3.652,5839,436319,430May 25 08:51 AM
GRAMMER ELIZABETH ASee RemarksMay 23 '23Sale3.652,3848,709330,451May 25 08:54 AM
Felsch Robert OraSee RemarksMay 23 '23Sale3.651,0463,821116,158May 25 08:55 AM
Rosenbaum David P.Chief Development OfficerMay 23 '23Sale3.659343,412112,162May 25 08:52 AM
Rosenbaum David P.Chief Development OfficerMar 29 '23Sale4.633,00013,888113,096Mar 31 06:50 PM